Newcastle disease virus infectious clones, vaccines and new diagnostic assays
View Patent ↗The invention relates to a process for generating infectious Newcastle disease virus (NDV) entirely from cloned full-length cDNA and to the use of vaccines and diagnostic assays generated with and derived from the process. The process offers the possibility to modify the NDV genome by means of genetic modification and allows for the introduction of mutations, deletions and/or insertions. The process can be used to modify the virulence of NDV, thus generating new attenuated live vaccines with enhanced properties. The process can be used to modify the antigenic make-up of NDV, to allow the generation of live NDV marker vaccines that can be serologically distinguished from NDV field strains.
1. A method for generating infectious copy avian paramyxovirus, wherein said avian paramyxovirus infectious copy is derived from Newcastle Disease Virus, the method comprising:
transfecting at least one cell with an avian-paramyxovirus cDNA comprising a nucleic acid sequence corresponding to the 5′-terminal end of the genome of avian paramyxovirus, as set forth in SEQ ED NO:82, and, further corresponding to the 3′-terminal end of the genome of avian-paramyxovirus, as set forth in SEQ ID NO:80 or SEQ ID NO:81, and further comprising a nucleic acid encoding a heterologous protein, wherein said heterologous protein is derived from a poultry pathogen selected from the group consisting of Avian Influenza, Avian leukosis virus, Chicken anemia virus, Marek's disease virus, Infectious laryngotracheitis virus, Infectious bursal disease virus, Turkey rhinotracheitis virus, Infectious bronchitis virus, Reoviruses, Adenoviruses, Pneumoviruses, Salmonella enteritidis, Campylobacter jejuni, Escherichia coli, Bordetella avium, Haemophilus paragallinarum, Pasteurella multocida, Ornithobacterium rhinotracheale, Riemerella anatipestifer , and Mycoplasma,
thus generating an infectious copy of avian paramyxovirus.
2. The method according to claim 1 wherein the at least one cell expresses viral nucleocapsid (NP), phospho-(P) or large polymerase (L) protein.
3. The method according to claim 1 further comprising: allowing cleavage of the avian-paramyxovirus' fusion protein.
4. The method according to claim 2 further comprising: allowing cleavage of the avian-paramyxovirus' fusion protein.
5. The method according to claim 1 further comprising incubating said cell in a growth medium having proteolytic activity.
6. The method according to claim 5 wherein said growth medium comprises allantoic fluid with proteolytic activity.
7. The method according to claim 2 further comprising incubating said cell in growth medium having proteolytic activity.
8. The method according to claim 6 wherein the growth medium comprises allantoic fluid with proteolytic activity.
9. The method according to claim 3 further comprising incubating said cell in growth medium having proteolytic activity.
10. The method according to claim 9 wherein said growth medium comprises allantoic fluid having proteolytic activity.
11. The method according to claim 1 wherein the cell is derived from a chicken cell.
12. A method for generating infectious copy avian paramyxovirus delved from Newcastle Disease Virus, the method comprising:
transfecting at least one cell with an avian-paramyxovirus cDNA comprising:
a nucleic acid sequence corresponding to the 5′-terminal end of the genome of avian paramyxovirus,
a nucleic acid encoding a heterologous protein, and
a modification comprising a nucleic acid encoding a hemaglutinin-neuraminidase (UN) protein,
the avian-paramyxovirus cDNA comprising a nucleic acid sequence corresponding to the 5′-terminal end, as set forth in SEQ ID NO:82, and, corresponding to the 3′-terminal end, as set forth in SEQ ID NO:81or SEQ ID NO:81, of the genome of avian-paramyxovirus, said nucleic acid sequence allowing generation of a replicating avian-paramyxovirus minigenome, wherein said avian-paramyxovirus is selected from the group consisting of avian paramyxovirus type-1, avian paramyxovirus type-2, avian paramyxovirus type-3, avian paramyxovirus type-4, avian paramyxovirus type-5, avian paramyxovirus type-6, avian paramyxovirus type-7, avian paramyxovirus type-8 and avian paramyxovirus type-9,
thus generating an infectious copy of avian paramyxovirus.
13. The method according to claim 1 wherein said Newcastle Disease Virus is a lentogenic virus.
14. The method according to claim 1 , wherein said avian-paramyxovirus cDNA has a modification in a nucleic acid.
15. The method according to claim 14 wherein said modification comprises a nucleic acid encoding a modified protease cleavage site.
16. The method according to claim 15 wherein said cleavage site is a protease cleavage site of the fusion (F) protein.
17. The method according to claim 14 wherein said modification comprises a nucleic acid encoding a hemaglutinin-neuraminidase (MN) protein.
18. The method according to claim 14 wherein the modification comprises a deletion in a nucleic acid encoding a viral protein.
19. The method according to claim 18 wherein the viral protein is a matrix (M) protein.
20. The method according to claim 1 wherein said avian-paramyxovirus cDNA further comprises a nucleic acid encoding an immune-stimulatory protein.